phospho-MAPKAPK5 (Ser93) Polyclonal Antibody
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-5505R |
| Product Name | phospho-MAPKAPK5 (Ser93) Polyclonal Antibody |
| Applications |
WB
ELISA
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human, Mouse, Rat |
| Predicted Reactivity | Dog, Cow, Horse, Chicken |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | KLH conjugated synthetic phosphopeptide derived from human MAPKAPK5 around the phosphorylation site of Ser93 |
| Modification Site | Ser93 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Shipped at 4_. Store at -20_ for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 8550 |
| Subcellular location | Cytoplasm, Nucleus |
| Synonyms | MAPKAPK5phospho S93; MAP kinase-activated protein kinase 5; MAPKAP kinase 5; MAPKAPK5; mitogen-activated protein kinase-activated protein kinase 5; p38-regulated/activated protein kinase. |
| Background | The serine/threonine kinase PRAK is activated in response to cellular stress and proinflammatory cytokines, through its phosphorylation by MAP kinases including MAPK1/ERK, MAPK14/p38 alpha, and MAPK11/p38 beta. PRAK has been reported to have a putative tumor suppressor function by mediating senescence upon activation by p38 in response to oncogenic ras. It is thought that phosphorylation of p53 by PRAK following activation of p38 MAPK by ras plays an important role in ras induced senescence and tumor suppression. |
| Application Dilution | |
| WB | 1:300-5000 |
| ELISA | 1:500-1000 |
| IHC-P | 1:200-400 |
| IHC-F | 1:100-500 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |